NCT01769352View on ClinicalTrials.gov

Treatment of Post-surgical Cystoid Macular Edema With Topical Steroids Trial (TEMPEST-1)

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions
Post-surgical Cystoid Macular Edema (PSCME)
Interventions
DRUG

PredA + Kelac

At week 12, patients will be determined to be resolved, improving/stabilized or treatment failures. Patients who have complete resolution of edema will begin treatment withdrawl. Improving/stabilizing patients will maintain current therapy. Treatment failure Group 2 patients will move to Group 3 to receive PredA q1h WA + Kelac qid starting at week 12. Treatment failure Group 1 patients will be exited from the trial so that alternative therapy can be given.

Trial Locations (1)

21287

Wilmer Eye Institute, Baltimore

All Listed Sponsors
lead

Johns Hopkins University

OTHER

NCT01769352 - Treatment of Post-surgical Cystoid Macular Edema With Topical Steroids Trial (TEMPEST-1) | Biotech Hunter | Biotech Hunter